乙酰半胱氨酸联合沙美特罗替卡松对稳定期COPD患者血清PCT、肺功能的影响

Effect of Acetylcysteine Combined with Salmeteroticasone on Serum PCT and Lung Function in Stable COPD Patients

目的 分析稳定期慢性阻塞性肺疾病(Chronic Obstructive Pulmonary Disease, COPD)患者联合应用乙酰半胱氨酸、沙美特罗替卡松治疗效果以及对血清降钙素原(Procalcitonin, PCT)、肺功能的影响。方法 单纯随机选取2021年1月—2023年11月黔西南布依族苗族自治州妇幼保健院收治的100例稳定期COPD患者为研究对象,按随机数表法分为对照组(n=50,单用沙美特罗替卡松治疗)、观察组(n=50,应用乙酰半胱氨酸联合沙美特罗替卡松治疗),比较两组治疗效率、症状消失时间、PCT水平、血清白介素水平、肺功能、不良反应发生率。结果 观察组治疗效率为90.00%,高于对照组的74.00%,差异有统计学意义(χ^(2)=4.336,P=0.037)。观察组咳嗽症状消失时间、咳痰症状消失时间、呼吸气促症状消失时间、干湿啰音消失时间均短于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组PCT、白细胞介素-6、白介素细胞-8水平低于对照组,差异有统计学意义(P均<0.05)。治疗后,观察组肺通气量、用力肺活量、最大呼吸流量高于对照组,差异有统计学意义(P均<0.05)。两组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论 稳定期COPD患者临床治疗过程中联合应用乙酰半胱氨酸、沙美特罗替卡松具有确切效果,能够加快症状消失,下调PCT与血清白介素表达,减轻肺功能损伤,并且未出现严重的药物不良反应,安全性高。

Objective To analyze the effects of acetylcysteine and salmeteroticasone on serum procalcitonin(PCT)and lung function in patients with stable chronic obstructive pulmonary disease(COPD).Methods A total of 100 patients with stable COPD admitted to the Qianxian Bouyei and Miao Autonomous Prefecture Maternal and Child Health Hospital of from January 2021 to November 2023 were simple randomly selected as the study subjects,and were divided into control group(n=50,treated with salmeteroticasone alone)and observation group(n=50,treated with acetyl cyste-ine and salmeteroticasone combined)according to random number table method.Treatment efficiency,symptom resolu-tion time,PCT and serum interleukin level,lung function and incidence of adverse reactions were compared between the two groups.Results The treatment efficiency of observation group was 90.00%,which was higher than 74.00%of control group,and the difference was statistically significant(χ^(2)=4.336,P=0.037).The disappearance time of cough symptom,sputum symptom,shortness of breath symptom and dry and wet rales in observation group were shorter than those in control group,and the differences were statistically significant(all P<0.05).After treatment,the level of PCT,interleukin-6 and interleukin-8 in observation group were lower than those in control group,and the differences were statistically significant(all P<0.05).After treatment,the maximum voluntary ventilation,forced vital capacity and peak expiratory flow in observation group were higher than those in control group,and the differences were statistically significant(all P<0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion In the course of clinical treatment of stable COPD patients,the combination of acetylcys-teine and salmeteroticasone has a definite effect,which can accelerate the disappearance of symptoms,down-regulate the expression of PCT and serum interleukin,reduce lung function injury,and no serious adverse drug reactions,with high safety.